Pricing updated 2019-02-20. Prices are subject to change without notice.
Pargyline is an irreversible inhibitor of monoamine oxidase (MAO; Kis = 15 and 1.8 μM for MAO-A and MAO-B, respectively).1 At 10 mg/kg i.v., pargyline induces a moderate decrease of systolic blood pressure in unanaesthetized hypertensive rats but not normotensive WKR or Sprague-Dawley rats.2 The correlation between the fall of blood pressure and the inhibition of brain MAO suggests that the accumulation of amine in brain is responsible for the fall in pressure.3 Reactive oxygen species-mediated monocyte hypertrophy is prevented by pargyline at a concentration of 10 µM.4 Formulations containing pargyline have been used to treat moderate hypertension.4,5
Warning - this product is not for human or veterinary use.
View the Cayman Structure Database for chemical structure definitions for many Cayman products
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data pack, and GC-MS data.
Fowler, C.J., Mantle, T.J., and Tipton, K.F. The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, l-
2. Fuentes, J.A., Ordaz, A., and Neff, N.H. Central mediation of the antihypertensive effect of pargyline in spontaneously hypertensive rats Eur. J. Pharmacol. 57(1), 21-27 (1979).
Yamori, Y., De Jong, W., Yamabe, H., et al. Effects of L-
Bianchi, P., Pimentel, D.R., Murphy, M.P., et al. A new hypertrophic mechanism of serotonin in cardiac myocytes: Receptor-
Puig, M., Wakade, A.R., and Kirpekar, S.M. Effect of the sympathetic nervous system of chronic treatment with parglyline and l-